(Press-News.org) SAN FRANCISCO, CA, December 6, 2014--In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology (ASH) highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.
For Classical Hodgkin lymphoma (cHL) patients, two phase I studies are already demonstrating dramatic results. A study led by Craig H. Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center (MSK), showed that 66 percent of cHL patients had a complete or partial response after receiving the immunotherapy drug pembrolizumab.
"These results are quite extraordinary given the dire circumstances these patients were facing," said Dr. Moskowitz. "Pembrolizumab has already been approved for patients with advanced melanoma and we're excited that the drug is producing responses in other cancer types."
Pembrolizumab is an inhibitor of PD-1, a protein on the surface of T cells that normally regulates the immune system by stopping T cell activation. Some cancers have developed ways of exploiting this shutdown mechanism by interacting with PD-1, enabling the cancer to escape T cell attack. Pembrolizumab blocks PD-1 from stopping T cell activation, allowing the T cells to keep fighting.
MSK physicians played a major role in the clinical trials that led to pembrolizumab's approval and are continuing to conduct trials using the therapy in melanoma, lymphoma, and other cancers.
Dr. Moskowitz's study examined pembrolizumab in 29 patients with cHL who had failed to respond to treatment with brentuximab vedotin. Twenty patients had also relapsed after autologous stem cell transplantation. "Phase I studies are designed for patients who have few, if any, treatment options left," added Dr. Moskowitz.
After twelve weeks, six patients (21 percent) achieved a complete response and thirteen patients (45 percent) went into partial remission. No serious adverse events were reported, and only one patient discontinued therapy because of a moderate side effect.
"Using the immune system as a weapon against cancer is just now beginning to gain momentum," said Dr. Moskowitz. "The results of this study are encouraging as we gather evidence that immunotherapies have the potential to work in many different types of cancer."
A second study presented at the ASH Annual Meeting and simultaneously published in the New England Journal of Medicine showed similarly positive results in cHL patients when using the immunotherapy drug nivolumab, another PD-1 inhibitor.
Twenty-three cHL patients who had failed prior treatment -- 18 of whom had also relapsed after autologous stem cell transplantation -- were given nivolumab. After 24 weeks, four patients (17 percent) achieved a complete response and sixteen patients (70 percent) went into partial remission. Only three serious adverse events were reported.
"These data are the first to be reported for a completed study of a PD-1 inhibitor in Classical Hodgkin lymphoma," said Alexander M. Lesokhin, MD, a medical oncologist at MSK who co-led the study. "This is good news for Hodgkin lymphoma patients and for the advancement of immunotherapies. It's an exciting time to be an oncologist."
Based on these results, the U.S. Food and Drug Administration granted nivolumab Breakthrough Therapy Designation in relapsed cHL. A large phase II trial of this therapy is underway at MSK and other institutions.
INFORMATION:
Dr. Moskowitz will present his study on pembrolizumab during an oral presentation at 7:15 AM PST on December 8. Abstract #290: PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)
The nivolumab study will be presented during an oral presentation at 7:00 AM PST on December 8. Abstract #289: Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study
About Memorial Sloan Kettering
We are the world's oldest and largest private cancer center, home to more than 13,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, we combine 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And our always-evolving educational programs continue to train new leaders in the field, here and around the world. For more information, go to http://www.mskcc.org.
PHOENIX -- In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic.
Their findings will be reported online Dec. 6 in the New England Journal of Medicine, and presented on Dec. 7 at the annual meeting of the American Society of Hematology (ASH), held in San Francisco.
Interim analysis of the ASPIRE clinical trial, which enrolled 792 patients with relapsed multiple myeloma ...
SAN FRANCISCO, CA, December 6, 2014--In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes. The study, led by Craig H. Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society ...
COLUMBIA, Mo. - Unconventional oil and gas (UOG) operations combine directional drilling and hydraulic fracturing, or "fracking," to release natural gas from underground rock. Recent discussions have centered on potential air and water pollution from chemicals used in these processes and how it affects the more than 15 million Americans living within one mile of UOG operations. Now, Susan C. Nagel, a researcher with the University of Missouri, and national colleagues have conducted the largest review to date of research centered on fracking byproducts and their effects ...
Researchers from the University of Hawai'i (UH) and NOAA's Office of National Marine Sanctuaries today announced the discovery of an intact "ghost ship" in 2,000 feet of water nearly 20 miles off the coast of Oahu. Sitting upright, its solitary mast still standing and the ship's wheel still in place, the hulk of the former cable ship Dickenson, later the USS Kailua, was found on the seabed last year on a maritime heritage submersible mission with the UH Hawai'i Undersea Research Laboratory's (HURL) Terry Kerby and Drs. James Delgado and Hans Van Tilburg of the maritime ...
Cold Spring Harbor, NY - Scientists at Cold Spring Harbor Laboratory (CSHL) have devised a powerful algorithm that improves the effectiveness of an important research technology harnessing RNA interference, or RNAi.
Discovered in the late 1990s, RNAi is a naturally occurring biological mechanism in which short RNA molecules bind to and "interfere" with messages sent by genes that contain instructions for protein production. Such interference can prevent a gene from being expressed. In addition to helping regulate gene expression, the RNAi pathway in many species, ...
LA JOLLA-Pain typically has a clear cause-but not always. When a person touches something hot or bumps into a sharp object, it's no surprise that it hurts. But for people with certain chronic pain disorders, including fibromyalgia and phantom limb pain, a gentle caress can result in agony.
In a major breakthrough, a team led by researchers at the Salk Institute and Harvard Medical School have identified an important neural mechanism in the spinal cord that appears to be capable of sending erroneous pain signals to the brain.
By charting the spinal circuits that process ...
When you go to bed and how long you sleep at a time might actually make it difficult for you to stop worrying, according to researchers at Binghamton University. The study, led by Binghamton Anxiety Clinic Director Meredith Coles and graduate student Jacob Nota, found that people who sleep for shorter periods of time and go to bed very late at night are often overwhelmed with more negative thoughts than those who keep more regular sleeping hours. The findings appear in Springer's journal Cognitive Therapy and Research, being published this month.
People are said to have ...
ANN ARBOR--An odd, iridescent material that's puzzled physicists for decades turns out to be an exotic state of matter that could open a new path to quantum computers and other next-generation electronics.
Physicists at the University of Michigan have discovered or confirmed several properties of the compound samarium hexaboride that raise hopes for finding the silicon of the quantum era. They say their results also close the case of how to classify the material--a mystery that has been investigated since the late 1960s.
The researchers provide the first direct evidence ...
(MEMPHIS, Tenn. - December 5, 2014) An international research collaborative has determined that a promising anti-malarial compound tricks the immune system to rapidly destroy red blood cells infected with the malaria parasite but leave healthy cells unharmed. St. Jude Children's Research Hospital scientists led the study, which appears in the current online early edition of the Proceedings of the National Academy of Sciences (PNAS).
The compound, (+)-SJ733, was developed from a molecule identified in a previous St. Jude-led study that helped to jumpstart worldwide anti-malarial ...
This news release is available in Spanish. This is a pioneering study in the world of the physiology of exercise, given that it describes for the first time that elite Kenyan athletes have greater brain oxygenation during periods of maximum physical effort, and which contributes to their success in long-distance races.
Doctor Jordan Santos-Concejero, of the Department of Physical Education and Sport at the UPV/EHU, carried out research the aim of which was to analyse the response of cerebral oxygenation at maximum and progressive rhythms amongst elite Kenyan runners ...
